“Novel Risk Model Using VAMP2 and VAMP5 Predicts Glioma Patient Prognosis and Immunotherapy Response”

https://pubmed.ncbi.nlm.nih.gov/38115820

A novel risk model based on the expression of VAMP2 and VAMP5 has been constructed and validated to help clinically predict the prognosis and response to immunotherapy of glioma patients.